The size, shape, margins, and structure of the ovaries, as observed in 26 patients with polycystic ovarian disease were analyzed, and uterine/ovarian ratio (maximum antero-posterior diameter of uterine fundus divided for longitudinal diameter of ovary) was calculated. The maximum surface area of the organs ranged from 9.5 cm2 to 17.3 cm2 (average value 12.9 cm2). A "roundness index" (minimum diameter X 100/maximum diameter) was calculated in order to evaluate the shape: it ranged from a value of 100 in perfectly rounded ovaries to a value of 54 in ovaries of oval shape. The ovarian structure was characterized by many small cysts of the same dimensions in 19 cases; in two patients there was a predominant cyst; in five cases it appeared as many thick echoes arranged along parallel lines. The uterine/ovarian ratio was always equal to or less than 1. Correlation tests for size, shape of the ovaries, patient's age, and duration of symptoms were highly significant. This leads one to suppose that both of these ultrasonic findings are a function of the duration of the disease and that polycystic ovarian disease, once established, is the cause of progressive enlargement of these organs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jcu.1870120106 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pathophysiology and diagnostic criteria of PCOS.
Minerva Obstet Gynecol
January 2025
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
Introduction: Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine-metabolic syndrome mainly characterized by ovarian dysfunction, which is only one manifestation of a more complex syndrome with a significant systemic impact.
Evidence Acquisition: We review scientific literature on the pathophysiology and diagnosis of PCOS evaluating the most relevant data from original articles, reviews and meta-analyses published until June 2024.
Evidence Synthesis: From a pathophysiological point of view, the concurrence of both metabolic aspects, such as insulin resistance and obesity, and hormonal alterations, such as hyperandrogenemia, might produce the most relevant clinical signs and/symptoms of this syndrome, for instance menstrual irregularities, hair loss, acne and hirsutism.
Three-dimensional MRI follicle segmentation and counting using SegmentWithSAM in the diagnosis of polycystic ovary syndrome.
Abdom Radiol (NY)
January 2025
Jinshan Hospital of Fudan University, Shanghai, China.
Objective: This study aimed to investigate the diagnostic performance of Follicle numbers measured on ultrasound (US), conventional magnetic resonance imaging (2D MRI), and three-dimensional (3D) MRI in patients with polycystic ovary syndrome (PCOS) and to compare the diagnostic efficacy of these imaging modalities.
Method: In this prospective study, 58 PCOS patients and 60 healthy women underwent US, conventional 2D MRI, and 3D MRI. Clinical laboratory tests and ovarian volume were compared between PCOS and control groups.
Effects of Liraglutide on Leptin Promoter Methylation in Ovarian Granulosa Cells of Obese Polycystic Ovary Syndrome Patients.
Tohoku J Exp Med
January 2025
Department of Obstetrics and Gynecology, Shanxi Fenyang Hospital.
Hyperoside mitigates PCOS-associated adipogenesis and insulin resistance by regulating NCOA2-mediated PPAR-γ ubiquitination and degradation.
Life Sci
January 2025
Departments of Gynaecology and Obstetrics, The Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China. Electronic address:
Aims: Polycystic ovary syndrome (PCOS) is closely associated with metabolic disorders such as insulin resistance and obesity, but the role of adipogenesis in its pathophysiology remains unclear. This study investigates the role of adipogenesis in PCOS development and evaluates whether hyperoside (HPS), an anti-adipogenic herbal compound, can improve PCOS by inhibiting adipogenesis.
Main Methods: A combination of in vivo and in vitro models was used to assess the impact of HPS on ovarian function, insulin resistance, and adipogenesis.
The role of Anti-Müllerian hormone in women health.
Ginekol Pol
January 2025
Department of Clinical Dietetics, Faculty of Health Sciences, Medical University of Warsaw, Poland, Poland.
Anti-Müllerian hormone (AMH), also known as Müller duct inhibitory factor and primarily known for its role in sexual differentiation. In female fetuses, AMH production by granulosa cells begins around the 36th week of gestation and continues in women until menopause. It is becoming more significant in the endocrine and gynecological diagnosis of adult women.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!